we study cancer tumors in all their complexity...

Cancer tumors are a complex mixture of normal and cancerous epithelia, immune effectors, and stromal elements that coordinate to inhibit host immunity and promote tumor growth, invasion, and metastasis. We study cancer tumors in all their complexity to best understand when and where potential cancer targets are expressed and how this expression is affected by drug treatment, changes in the extracellular matrix, and the presence or absence of immune effectors. Using a combination of cutting edge and proprietary proteomics, transcriptomics, and bioinformatics methods; primary and recurrent tumors are interrogated and differentially expressed cancer antigens are selected for inclusion in our portfolio for therapeutic antibody development. Bluefin Biomedicine is focused on developing effective antibody-based treatments for orphan cancer indications that will impact underserved patients.